Secondary malignant neoplasms are important late complications after chemotherapy and/or radiotherapy in cancer patients. Therapy-related malignancies include acute leukemia, myelodysplastic syndrome (MDS), lymphoma, and solid tumors. However, secondary acute lymphoid leukemia or chronic myeloid leukemia (CML) is rarely reported.
/L with 3% promyelocyte, 15% myelocyte, 19% metamyelocytes, 48% neutrophils, 4% lymphocytes, and 11% monocytes; and platelet count 81 × 10 9 /L. The liver and renal functions were in normal range with increased lactate dehydrogenase at 435.4 IU/L (normal range 109.0-245.0). Bone marrow cells were collected and performed the following examinations: (a) cytology showed marked hypercellular marrow with 2.5% myeloblasts, 4.5% promyelocyte, 31.5% myelocyte, 14.5% metamyelocytes, increased number of megakaryocytes, and neutrophil alkaline phosphatase score at 30 (normal range 13-130); (b) cytogenetic analysis revealed 46, XY, t(9;22)(q34; q11.2) in 10 of 10 metaphase cells; (c) molecular analysis by quantitative polymerase chain reaction found P190 positive with negative results for P210 and P230. The diagnosis of CML in the chronic phase was made.
The patient was locally born, worked as a teacher, and did not have relevant family history. He was treated with colchicines for gout for 4 months before the diagnosis of CML. The present case was strongly suspected to be therapy-related leukemia as he was treated with S-1 plus oxaliplatin for gastric cancer. The patient has been treated with imatinib mesylate 300 mg daily from June 2015 and achieved complete hematologic response in 1.5 months. The patient discontinued imatinib due to rash and switched to dasatinib 50 mg daily in September In CML, the breakpoints in BCR gene on chromosome 22 (usually between exons e12-e16) and ABL gene on chromosome 9 (in exon a2) result in fusion transcripts encoded for P210 BCR-ABL . In rare case, fusion transcript involving e1a2 may occur which encodes P190 BCR-ABL . [2, 3] These two transcripts may coexist, but P190 BCR-ABL CML only is uncommon representing only 1% of CML. The clinical manifestations and outcome of CML bearing P190 BCR-ABL are different from those with P210 BCR-ABL , demonstrating inferior response to tyrosine kinase inhibitors. P190 BCR-ABL CML has been reported to have increased monocytosis and splenomegaly. [4, 5] Based on medical history and molecular data, the patient was diagnosed secondary P190 BCR-ABL CML and showed monocytosis.
Secondary malignancies are a severe complication after successful chemotherapy and/or radiotherapy for primary malignancy. As a rare complication, secondary CML comprises approximately 2.6% of total secondary leukemia case and secondary P190
BCR-ABL CML is far less. Therefore, secondary CML following S-1 treatment is rarely reported. S-1 is an oral fluoropyrimidine, belonging to antimetabolites. In addition to S-1, the patient received oxaliplatin therapy. There was one case report showing secondary acute promyelocytic leukemia following oxaliplatin plus capecitabine therapy [6] while secondary CML following oxaliplatin was not reported yet. As the molecular or cytogenetic data were not available at the diagnosis of gastric adenocarcinoma, we cannot rule out the possibility of existing CML at the diagnosis of gastric adenocarcinoma. However, this case is very likely to be therapy related from the fact that S-1 and oxaliplatin were administrated 2 years before the diagnosis of CML. Compared to the earlier case reports, [7, 8] this patient was exposed to shorter duration and fewer doses of S-1.
Reasonable amount of data is available regarding the epidemiology, molecular pathogenesis, clinical manifestations, and treatment response of secondary AML and MDS; however, very little is known about therapy-related CML. Therapy-related CML cannot be distinguished from de novo cases both cytogenetically and clinically. Up to now, evidence is lacking as to the frequency of therapy-related CML complicating cytotoxic therapy. It is suggested that complete blood count should be monitored following cancer treatment.
Therapy-related CML is a rare late complication of cytotoxic therapy. It is suggested that complete blood count should be monitored after chemotherapeutic treatment of cancer.
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